Glutamate Antagonists in Amyotrophic Lateral Sclerosis: A Review of Their Therapeutic Potential

CNS Drugs

Volumn 5, Issue 6, 1996, Pages 437-456

  Plaitakis, Andreas ^a,b   Fesdjian, Christina O ^a   Shashidharan, Pullanipally ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; AMINO ACID RECEPTOR BLOCKING AGENT; BRANCHED CHAIN AMINO ACID; GABAPENTIN; GLUTAMATE RECEPTOR ANTAGONIST; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0029993223     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605060-00004     Document Type: Article

References (110)

1. Kurtzke JF, Kurland LT. The epidemiology of neurologic disease. In: Joynt RJ, editor. Clinical neurology. Philadelphia: J.B. Lippincott, 1989: 1-43
2. Tyler HR, Shefner J. Amyotrophic lateral sclerosis. In: de Jong JMBV, editor. Handbook of clinical neurology. Vol 15 (59). Diseases of the motor system. Amsterdam: Elsevier, 1991: 169-215
3. Plaitakis A. Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: a hypothesis. Ann Neurol 1990; 28: 3-8
4. Rosen DR, Siddique T, Patterson D, et al. Mutations in CU/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62
5. Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SODI mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995; 14: 1105-16
6. Plaitakis A, Shashidharan P. Amyotrophic lateral sclerosis, glutamate, and oxidative stress. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 1532-43
7. Plaitakis A, Smith J, Mandeli J, et al. Pilot trial of branched-chain amino acids in amyotrophic lateral sclerosis. Lancet 1988; 1: 1015-8
8. Eisen A, Stewart H, Schulzer M, et al. Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can J Neurol Sci 1993; 20: 297-301
9. Askmark H, Aquilonius S-M, Gilberg P-G, et al. A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1993; 56: 197-200
10. Bensimon G, Lasomblez L, Meininger V, the ALS/Riluzole group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585-91
11. Fonnum F, Glutamate: a neurotransmitter in mammalian brain. J Neurochem 1984; 42: 1-11
12. Young AB, Penney JB, Dauth GW, et al. Glutamate or aspartate as a possible neurotransmitter of the cerebral cortico-fugal fibers in the monkey. Neurology 1983; 33: 1513-6
13. Brann DW. Glutamate: a major excitatory transmitter in neuroendocrine regulation. Neuroendocrinology 1995; 61: 213-25
14. Nicholls DG. The glutamatergic nerve terminal. Eur J Biochem 1993; 212: 613-31
15. Danbolt NC. The high affinity uptake system for excitatory amino acids in brain. Prog Neurobiol 1994; 44: 377-96
16. Pines G, Danbolt NC, Bjoras M, et al. Cloning and expression of a rat brain L-glutamate transporter. Nature 1992; 360: 464-7
17. +-dependent glutamate/aspartate transporter from rat brain. Proc Natl Acad Sci USA 1992; 89: 10955-9
18. Kanai Y, Hediger MA. Primary structure and functional characterization of a high-affinity glutamate transporter. Nature 1992; 360: 420-1
19. Shashidharan P, Plaitakis A. Cloning and characterization of a glutamate transporter cDNA from human cerebellum. Biochem Biophys Acta 1993; 1216: 161-4
20. Shashidharan P, Wittenberg I, Plaitakis A. Molecular cloning of human glutamate/aspartate transporter: II. Biochem Biophys Acta 1944; 1191: 393-6
21. Shashidharan P, Huntley GW, Meyer T, et al. Neuron-specific human glutamate transporter: molecular cloning, characterization and expression in human brain. Brain Res 1994; 662: 245-50
22. Arizza JL, Fairman WA, Wadiche JI. Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J Neurosci 1994; 14: 5559-69
23. Fairman WA, Vandenberg RF, Ariza JL, et al. An excitatory amino-acid transporter with properties of a ligand-gated chloride channel. Nature 1995; 375: 599-603
24. Shank RP, Aprison MH. Glutamate as neurotransmitter. In: Kvamme E, editor. Glutamine and glutamate in mammals. Vol. II. Boca Raton (FL): CRC Press, 1989: 3-19
25. Hertz A, Schousboe A. Metabolism of glutamate and glutamine in neurons and astrocyctes in primary cultures. In: Kvamme E, editor. Glutamine and glutamate in mammals. Vol II. Boca Raton (FL): CRC Press, 1988: 39-55
26. 2 fixation in mammalian brain in vivo. J Neurochem 1964; 11: 717-28
27. Wheal HV, Thomson AM, editors. Excitatory amino acids and synaptic transmission. London: Academic Press, 1991
28. McBurney RN. Therapeutic potential of NMDA antagonists in neurodegenerative diseases. Neurobiol Aging 1994; 15: 271-5
29. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992; 258: 597-603
30. Schoepp DD, Sacaan AI. Metabotropic glutamate receptors and neuronal degenerative disorders. Neurobiol Aging 1994; 15: 261-3
31. Ambrosini A, Bresciani L, Fracchia S, et al. Metabotropic receptors negatively coupled to adenylate cyclase inhibit N-methyl-D-aspartate receptor activity and prevent neurotoxicity in mesencephalic neurons in vitro. Mol Pharmacol 1995; 47: 1057-64
32. Graham ME, Burgoyne RD. Activation of metabotropic glutamate receptors by L-AP4 stimulates survival of rat cerebellar granule cells in culture. Eur J Pharmacol 1994; 288: 115-23
33. Plaitakis A, Caroscio JT. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 1987; 22: 575-9
34. Blin O, Desnuelle C, Guelton C, et al. Clinique des maladies du système nerveux cl de l'appareil locomoteur. Rev Neurol 1991; 147: 292-4
35. Iwasaki Y, Ikeda K, Kinoshita M. Plasma amino acid levels in patients with amyotrophic lateral sclerosis. J Neurol Sci 1992; 107: 219-22
36. Bastone A, Micheli A, Beghi E, et al. The imbalance of brain large-chain amino acid availability in amyotrophic lateral sclerosis patients treated with high doses of branched-chain amino acids. Neurochem Int 1995; 27: 467-72
37. Perry TL, Krieger C, Hansen S, et al. Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid. Ann Neurol 1990; 28: 12-7
38. Young AB. What's the excitement about excitatory amino acids in amyotrophic lateral sclerosis? Ann Neurol 1990; 28: 9-11
39. Plaitakis A, Mandeli J, Fesdjian CO, et al. Dysregulation of glutamate in ALS: correlation with gender and disease type. Neurology 1990; 41 Suppl. 1: 392-3
40. Camu W, Billiard M, Baldy-Moulinier M. Fasting plasma and CSF amino acid levels in amyotrophic lateral sclerosis: a subtype analysis. Acta Neurol Scand 1993; 88: 51-5
41. Rothstein JD, Tsai G, Kunel RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28: 18-25
42. Rothstein JD, Kunel R, Chaudhry V, et al. Excitatory amino acids in amyotrophic lateral sclerosis: an update. Ann Neurol 1991; 30: 224-5
43. Blin O, Samuel D, Nieoullon A, et al. Changes in CSF amino acid concentrations during the evolution of amyotrophic lateral sclerosis. J Neurol Neurosurg Psych 1994; 57: 119-21
44. Perry TL, Hansen S, Jones K. Brain glutamate deficiency in amyotrophic lateral sclerosis. Neurology 1987; 37: 1845-8
45. Plaitakis A, Constantakakis E, Smith J. The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 1988; 24: 446-9
46. Malessa S, Leigh PN, Bertel O, et al. Amyotrophic lateral sclerosis, glutamate dehydrogenase and transmitter amino acids in the spinal cord. J Neurol Neurosurg Psych 1991; 54: 984-8
47. Tsai GC, Stauch-Sluser B, Sim L, et al. Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis. Brain Res 1991; 556: 151-6
48. Constantakakis E, Plaitakis A. N-acetyl-aspartate and N-acetylaspartyl-glutamate are altered in amyotrophic lateral sclerosis [abstract]. Ann Neurol 1988; 24: 478
49. Plaitakis A. Altered glutamatergic mechanisms and selective motor neuron degeneration in amyotrophic lateral sclerosis: possible role for glycine. Adv Neurol 1991; 56: 319-36
50. Rothstein JD, Martin LJ, Kunel RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992; 326: 1464-8
51. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38: 73-84
52. Levy LN, Lehre KP, Waalas I, et al. Down regulation of a glial glutamate transporter in striatum alter destruction of the glutamatergic corticospinal projection [abstract]. J Neurochem 1993; 61: S208
53. Torp R, Lekieffre D, Levy LM, et al. Reduced postischemic expression of a glial glutamate transporter, GLT1, in rat hippocampus. Exp Brain Res 1995; 103: 51-8
54. Rothstein JD, Bristol LA. Glutamate transporter mRNA is not altered in amyotrophic lateral sclerosis motor cortex [abstract]. Neurology 1996; 46: P05.017
55. Battaglioli G, Martin DL, Plummer J. et al. Synaptosomal glutamate uptake declines progressively in the spinal cord of a mutant mouse with motor neuron disease. J Neurochem 1993; 60: 1567-9
56. Ikonomidou C, Qin YQ, Labruyere J, et al. Motor neuron degeneration induced by excitotoxin agonists has features in common with those seen in SOD-1 transgenic mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1996; 55: 211-24
57. McNamara JO, Fridovich I. Did radicals strike Lou Gehrig? Nature 1993; 362: 20-1
58. Arancio O, Mac Dermott AB. Differential distribution of excitatory amino acid receptors on embryonic rat spinal cord neurons in culture. J Neurophysiol 1991; 65: 899-913
59. Mitchell JJ, Anderson KJ. Quantitative autoradiographic analysis of excitatory amino acid receptors in the cat spinal cord. Neurosci Lett 1991; 124: 269-72
60. Shaw PJ, Ince PG, Johnson M, et al. The quantitative autoradiographic distribution of [3H]MK-801 binding sites in the normal human spinal cord. Brain Res 1991; 539: 164-8
61. Rothstein JD, Martin L, Levey AI, et al. Localization of neuronal and glial glutamate transporters. Neuron 1994; 13: 713-25
62. Mayer ML, Ladislav Jr V, Clements J. Regulation of NMDA receptor desensitization in mouse hippocampal neurons by glycine. Nature 1989; 338: 425-7
63. Allaoua H, Chaudieu I, Krieger C, et al. Alterations in spinal cord excitatory amino acid receptors in amyotrophic lateral sclerosis. Brain Res 1992; 579: 169-72
64. Krieger C, Wagey R, Shaw C. Amyotrophic lateral sclerosis: quantitative autoradiography of [3H]MK-801/NMDA binding sites in spinal cord. Neurosci Lett 1993; 159: 191-4
65. Shaw PJ, Ince PG, Matthews JN, et al. N-methyl-D-aspartate (NMDA) receptors in the spinal cord and motor cortex in motor neuron disease: a quantitative autoradiographic study using [3H]MK-801. Brain Res 1994; 637: 297-302
66. Shaw PJ, Ince PG, Johnson M, et al. The quantitative autoradiographic distribution of [3H]MK-801 binding sites in the normal human brainstem in relation to motor neuron disease. Brain Res 1992; 572: 276-80
67. Regan RF, Choi DW. Glutamate neurotoxicity in spinal cord cell culture. Neuroscience 1991; 43: 585-91
68. Mentis GZ, Greensmity L, Vrbova G. Motor neurons destined to die are rescued by blocking N-methyl-D-aspartate receptors by MK-801. Neuroscience 1993; 54: 283-5
69. Yum SW, Faden AI. Comparison of the neuroprotectivc effects of the N-methyl-D-aspartate antagonist MK-801 and the opiate-receptor antagonist nalmefene in experimental spinal cord injury. Arch Neurol 1990; 46: 277-81
70. Rothstein JD, Jin L, Dykes-Hoberg M, et al. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 1993; 90: 6591-5
71. Kuypers HGJM. Anatomy of the descending pathways. In: Brookhart JM, Mountcastle VB, Brooks VB, editors. Handbook of physiology. Section 1. The nervous system. Vol II. Motor control. Bethesda: American Physiological Society, 1981: 597-662
72. Rothstein JD, Kunel RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 1995; 65: 643-51
73. Dugan LL, Choi DW. Excitotoxicity, free radicals and cell membrane changes. Ann Neurol 1994; 35: S17-21
74. Billups B, Attwell D. Modulation of non-vesicular glutamate release by pH. Nature 1996; 379: 171-4
75. Burke SP, Nadler JV. Regulation of glutamate and aspartate release from slices of the hippocampal CA1 area: effects of adenosine and baclofen. J Neurochem 1988; 51: 1541-51
76. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993; 250: 473-6
77. Brodie MJ, Lamotrigine. Lancet 1992; 339: 1397-400
78. Chittajallu R, Vignes M, Dev KK, et al. Regulation of glutamate release by presynaptic kainate receptors in the hippocampus. Nature 1996; 379: 78-81
79. Casado M, Bendaham A, Zafra F, et al. Phosphorylation and modulation of brain glutamate transporters ny protein kinase C. J Biol Chem 1993; 268: 27313-7
80. Voisin P, Viratelle O, Girault JM, et al. Plasticity of astroglial glutamate and gamma-aminobutyric uptake in cell cultures derived from postnatal mouse cerebellum. J Neurochem 1993; 60: 114-27
81. McKenna MC, Snnewald U, Huang X, et al. Exogenous glutamate concentration regulates metabolic fate of glutamate in astrocytes. J Neurochem 1996; 66: 386-93
82. Rothe F, Brosz M, Storm-Mathisen J. Quantitative ultrastructural localization of glutamate dehydrogenase in the rat cerebellar cortex. Neuroscience 1994; 62: 1133-46
83. Shashidharan P, Michaelides TM, Robakis NK, et al. Novel human glutamate dehydrogenase expressed in neural and testicular tissues and encoded by an X-linked intronless gene. J Biol Chem 1994; 269: 16971-6
84. Erecinska M, Nelson D. Activation of glutamate dehydrogenase by leucine and its non-metabolizable analogue in rat brain synaptosomes. J Neurochem 1990; 54: 1335-43
85. Romano C, Price MT, Olney JW. Delayed excitotoxic neurodegeneration induced by excitatory amino acid agonists in isolated retina. J Neurochem 1995; 65: 59-67
86. Vornov JJ, Tasker RC, Park J. Neurotoxicity of acute glutamate transport blockade depends on coactivation of both NMDA and AMPA/kainate receptors in organotypic hippocampal cultures. Exp Neurol 1995; 133: 7-17
87. Olney JW. Neurotoxicity of NMDA receptor antagonists: an overview. Psychopharmacol Bull 1994; 30: 533-40
88. Baran H, Loscher W, Mevissen M. The glycine/NMDA receptor partial agonist D-cycloserine blocks kainate-induced seizures in rats. Comparison with MK-801 and diazepam. Brain Res 1994; 652: 195-200
89. Taylor LA, McQuabe RD, Tice MA. Felbamate, a novel antiepileptic drug, reverses N-methyl-D-aspartate/glycine-stimulated increases in intracellular CA2+ concentration. Eur J Pharmacol 1995; 289: 229-33
90. Lynch JJ, Shan PYU, Lorella MT, et al. Sodium channel blockers reduce oxygen-glucose deprivation-induced cortical neuronal injury when combined with glutamate receptor antagonists. J Pharmacol Exp Ther 1995; 273: 554-60
91. Plaitakis A, Shashidharan P. Branched chain amino acids in amyotrophic lateral sclerosis [letter]. Lancet 1988; II: 680
92. Plaitakis A, Manganas E. Branched-chain amino acids and glutamatergic transmission in amyotrophic lateral sclerosis. In: Schauder P, Wahren J, Paoletti R, et al., editors. Branched-chain amino acids: biochemistry, physiology, and clinical sciences. New York: Raven Press, 1992: 137-55
93. Plaitakis A, Sivak M, Fesdjian CO, et al. Treatment of amyotrophic lateral sclerosis with branched chain amino acids (BCAA): results of a second trial [abstract]. Neurology 1992; 42 Suppl. 3: 454
94. Testa D, Caraceni T, Feloni V. Branched-chain amino acids and amyotrophic lateral sclerosis. J Neurol 1989; 236: 445-7
95. The Italian ALS Study Group. Branched chain amino acids and amyotrophic lateral sclerosis: a treatment failure? Neurology 1993; 43: 2466-70
96. Marchesini G, Dioguardi FS, Biarchi GR, et al. Long-term oral branched-chain amino acid treatment in hepatic encephalopathy. J Hepatol 1990; 11: 92-101
97. Yudkoff M, Daikhin Y, Lin Z-P, et al. Interrelationships of leucine and glutamate metabolism in cultured astrocytes. J Neurochem 1994; 62: 1192-202
98. Steiner T for SPECIALS. Multinational trial of branched-chain amino acids in amyotrophic lateral sclerosis [abstract]. Muscle Nerve 1994; Suppl. 1: S166
99. Taylor CP. Emerging perspectives on the mechanism of action of gabapentin. Neurology 1994; 44 Suppl. 5: S10-6
100. Su TZ, Lunney E, Campbell G, et al. Transport of gabapentin, a gamma-amino acid drug, by system 1 alpha-amino acid transporters: a comparative study in astrocytes, synaptosomes and CHO cells. J Neurochem 1995; 64: 2125-31
101. Miller RG, Gelinas D, Moore D, et al. A placebo-controlled trial of gabapentin in amyotrophic lateral sclerosis [abstract]. Neurology 1996; 46: S64.002
102. Hebert T, Drapeau P, Pradier L, et al. Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol 1994; 45: 1055-60
103. Hubert JP, Delumeau JC, Glowinski J, et al. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for dual mechanism of action. Br J Pharmacol 1994; 113: 261-7
104. Mantz J, Laudernbach V, Lecharny JB, et al. Riluzole, a novel antiglutamate, blocks GABA uptake by striatal synaptosomes. Eur J Pharmacol 1994; 257: R7-8
105. Rhône-Poulenc Rorer. Rilutek® riluzole: package insert. Rhône-Poulenc Rorer Pharmaecuticals Inc., Collegeville (PA), 1995
106. Rowland LP. Riluzole for the treatment of amyotrophic lateral sclerosis too soon to tell? Nature 1994; 330: 636-7
107. McKee P, Fuller GN, Stevens DL. Riluzole in amyotrophic lateral sclerosis [letter]. N Engl J Med 1994; 331: 272
108. MacRae KD. Riluzole in amyotrophic lateral sclerosis [letter]. N Engl J Med 1944; 331: 272
109. Murphy JR. Riluzole in amyotrophic lateral sclerosis [letter]. N Engl J Med 1994; 331: 273
110. Hollander D, Pradas J, Kaplan R, et al. High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studies. Ann Neurol 1994; 36: 920-4